Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01095666
First received: March 26, 2010
Last updated: June 6, 2014
Last verified: June 2014
  Purpose

The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in Asian patients with Type 2 Diabetes who are not well controlled on metformin alone. The safety of this treatment will also be studied.


Condition Intervention Phase
Type 2 Diabetes
Drug: Dapagliflozin
Drug: Metformin
Drug: Dapagliflozin Placebo
Drug: Pioglitazone
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Change from baseline in HbA1c for each dose of dapagliflozin vs placebo [ Time Frame: At Week 24 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from baseline in Fasting Plasma Glucose (FPG) [ Time Frame: At Week 24 ] [ Designated as safety issue: No ]
  • Change from baseline in 2hr-post meal glucose [ Time Frame: At Week 24 ] [ Designated as safety issue: No ]
  • Proportion of subjects achieving a therapeutic glycemic response, defined as HbA1c < 7.0% [ Time Frame: At Week 24 ] [ Designated as safety issue: No ]
  • Change from baseline in total body weight [ Time Frame: At Week 24 ] [ Designated as safety issue: No ]

Enrollment: 445
Study Start Date: June 2010
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group 1 Drug: Dapagliflozin
Tablets, Oral, 5 mg, Once daily, 24 weeks
Other Name: BMS-512148
Drug: Metformin
Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
Other Name: Glucophage®
Drug: Dapagliflozin Placebo
Tablets, Oral, 0 mg, Once daily, 24 weeks
Drug: Pioglitazone
Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
Experimental: Group 2 Drug: Dapagliflozin
Tablets, Oral, 10 mg, Once daily, 24 weeks
Other Name: BMS-512148
Drug: Metformin
Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
Other Name: Glucophage®
Drug: Dapagliflozin Placebo
Tablets, Oral, 0 mg, Once daily, 24 weeks
Drug: Pioglitazone
Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
Experimental: Group 3 Drug: Metformin
Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
Other Name: Glucophage®
Drug: Dapagliflozin Placebo
Tablets, Oral, 0 mg, Once daily, 24 weeks
Drug: Pioglitazone
Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and females, 18 to 77 years old, with type 2 diabetes and with inadequate glycemic control
  • Drug naive or treated with anti-diabetic medication for < 24 weeks
  • C-peptide ≥ 1.0 ng/mL
  • Body Mass Index ≤ 45.0 kg/m²

Exclusion Criteria:

  • AST and/or ALT > 3 times ULN
  • Serum total bilirubin > 2 mg/dL
  • Serum creatinine ≥ 1.50 mg/dL for men or ≥ 1.40 mg/dL for women
  • Creatine kinase ≥ 3 times ULN
  • Symptoms of severely uncontrolled diabetes
  • Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01095666

  Hide Study Locations
Locations
China, Anhui
Local Institution
Hefei, Anhui, China, 230022
China, Beijing
Local Institution
Beijing, Beijing, China, 100730
Local Institution
Beijing, Beijing, China, 100700
Local Institution
Beijing, Beijing, China, 100029
Local Institution
Beijing, Beijing, China, 100001
Local Institution
Beijing, Beijing, China, 100044
China, Chongqing
Local Institution
Chongqing, Chongqing, China, 400016
China, Guangdong
Local Institution
Guangzhou, Guangdong, China, 510120
China, Heilongjiang
Local Institution
Haerbin, Heilongjiang, China, 150001
China, Hunan
Local Institution
Changsha, Hunan, China, 410008
Local Institution
Changsha, Hunan, China, 410000
China, Jiangsu
Local Institution
Nanjing, Jiangsu, China, 210006
Local Institution
Nanjing, Jiangsu, China, 210008
Local Institution
Wuxi, Jiangsu, China, 214023
China, Jilin
Local Institution
Changchun, Jilin, China, 130041
China, Liaoning
Local Institution
Shenyang, Liaoning, China, 110003
China, Shanghai
Local Institution
Shanghai, Shanghai, China, 200040
Local Institution
Shanghai, Shanghai, China, 200065
Local Institution
Shanghai, Shanghai, China, 200003
China, Sichuan
Local Institution
Chengdu, Sichuan, China, 610070
Local Institution
Chongqing, Sichuan, China, 400010
China, Tianjin
Local Institution
Tianjin, Tianjin, China, 300211
China, Zhejiang
Local Institution
Hangzhou, Zhejiang, China, 310009
China
Local Institution
Xi'An, China, 710032
India
Local Institution
Bangalore, Karnataka, India, 560 043
Local Institution
Indore, Madhya Pradesh, India, 452010
Local Institution
Bangalore, India, 560092
Local Institution
Jaipur, India, 302023
Local Institution
Vellore, Tamilnadu, India, 632004
Korea, Republic of
Local Institution
Seoul, Nowon-Gu, Korea, Republic of, 139-711
Local Institution
Busan, Korea, Republic of, 614-735
Local Institution
Seoul, Korea, Republic of, 120-752
Local Institution
Seoul, Korea, Republic of, 137-040
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01095666     History of Changes
Other Study ID Numbers: MB102-055
Study First Received: March 26, 2010
Last Updated: June 6, 2014
Health Authority: China: Food and Drug Administration
India: Drugs Controller General of India
Korea: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Metformin
Pioglitazone
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 19, 2014